How Big Pharma Has Responded To FTC Delisting Demands
The Federal Trade Commission under former Chair Lina Khan expressed concerns about high prescription drug prices and believed that improper patent protection was partly responsible for it. Under Chair Andrew Ferguson,...To view the full article, register now.
Already a subscriber? Click here to view full article